(Q43645743)

25 November 2017

Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia (English)

1 reference

25 November 2017

1 reference

Jian-Jun Ou

1

1 reference

25 November 2017

Yi Xu

2

1 reference

25 November 2017

Hong-Hui Chen

3

1 reference

25 November 2017

Xiaoduo Fan

4

1 reference

25 November 2017

Keming Gao

5

1 reference

25 November 2017

Juan Wang

6

1 reference

25 November 2017

Xiao-Feng Guo

7

1 reference

25 November 2017

Ren-Rong Wu

8

1 reference

25 November 2017

Jing-Ping Zhao

9

1 reference

25 November 2017

28 August 2012

1 reference

25 November 2017

9

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

25 November 2017

225

1 reference

25 November 2017

3

1 reference

25 November 2017

627-635

1 reference

https://scigraph.springernature.com/pub.10.1007/s00213-012-2850-6

25 November 2017

0 references

cites work

Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

Use and abuse of HOMA modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2850-6

Ziprasidone versus other atypical antipsychotics for schizophrenia

21 January 2018

1 reference

12 December 2020

Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

1 reference

12 December 2020

Weight gain with atypical antipsychotics: evidence and insights.

1 reference

12 December 2020

Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Olanzapine versus other atypical antipsychotics for schizophrenia

1 reference

12 December 2020

Weight gain associated with use of psychotropic medications

1 reference

12 December 2020

Mortality and medical comorbidity among patients with serious mental illness.

1 reference

12 December 2020

An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990.

1 reference

12 December 2020

10.1007/S00213-012-2850-6

Identifiers

DOI

1 reference

Dimensions Publication ID

25 November 2017

0 references

1 reference